Penumbra Inc PEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PEN is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $201.96
- Day Range
- $200.90–203.70
- 52-Week Range
- $181.03–346.71
- Bid/Ask
- $201.52 / $202.14
- Market Cap
- $7.81 Bil
- Volume/Avg
- 27,393 / 349,901
Key Statistics
- Price/Earnings (Normalized)
- 135.46
- Price/Sales
- 7.48
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 4,200
- Website
- https://www.penumbrainc.com
Comparables
Valuation
|
Metric
|
PEN
|
MMSI
|
ZIMV
|
|---|---|---|---|
Price/Earnings (Normalized) | 135.46 | 23.58 | 9.61 |
Price/Book Value | 6.62 | 3.42 | 1.04 |
Price/Sales | 7.48 | 3.29 | 0.91 |
Price/Cash Flow | 44.87 | 19.25 | 12.19 |
Price/Earnings
PEN
MMSI
ZIMV
Financial Strength
|
Metric
|
PEN
|
MMSI
|
ZIMV
|
|---|---|---|---|
Quick Ratio | 3.25 | 3.81 | 0.84 |
Current Ratio | 6.06 | 5.45 | 2.78 |
Interest Coverage | 42.88 | 8.07 | −1.51 |
Quick Ratio
PEN
MMSI
ZIMV
Profitability
|
Metric
|
PEN
|
MMSI
|
ZIMV
|
|---|---|---|---|
Return on Assets (Normalized) | 5.67% | 9.43% | 14.12% |
Return on Equity (Normalized) | 7.62% | 14.77% | 31.63% |
Return on Invested Capital (Normalized) | 5.96% | 11.47% | 18.79% |
Return on Assets
PEN
MMSI
ZIMV
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Bwjjykvy | Pwjdcc | $182.7 Bil | |
SYK
| Stryker Corp | Ktywvhkrwd | Zrwrw | $124.6 Bil | |
MDT
| Medtronic PLC | Hnycdywsj | Cblsdf | $105.2 Bil | |
BSX
| Boston Scientific Corp | Clmpljcz | Gwymf | $99.1 Bil | |
EW
| Edwards Lifesciences Corp | Trdzxxsjs | Zfyhdl | $52.0 Bil | |
DXCM
| DexCom Inc | Qxlrbcsgl | Gdxyv | $51.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Tglpqrdfb | Zybl | $24.5 Bil | |
ALGN
| Align Technology Inc | Dbvmlxfw | Xqsjpd | $22.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Dhvfcfmv | Ccrkdq | $18.3 Bil | |
PODD
| Insulet Corp | Xzrgrnddc | Pmltl | $11.6 Bil |